Oncologists favor biosimilar adoption, Decision Resources finds
BURLINGTON, Mass. While biosimilars promise to provide therapies for a wide range of diseases, their biggest fans may come from cancer specialists, according to a new report.
Healthcare market research firm Decision Resources found in a report that oncologists would be the most aggressive in adopting biosimilars compared with other specialists because of their lower clinical trial requirements. According to research, oncologists in the United States will adopt biosimilars faster than their European counterparts because they will require fewer and shorter phase-3 clinical trials before they feel comfortable prescribing them.
The firm expected biosimilars of granulocyte colony-stimulating factor, as well as biosimilars of monoclonal antibody therapies used to treat cancer, to reduce brand sales by more than $7 billion in 2019 in the United States, Japan, the United Kingdom, France, Germany, Italy and Spain, which Decision Resources collectively refers to as the “EU5.”
“Because of patent expiries and more-established regulatory pathways for approving biosimilars in Europe, most biosimilar [monoclonal antibodies] will launch in the EU5 before the United States,” Decision Resources analyst Cindy Fung said. “As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents.”
Rite Aid highlights patients’ favorite pharmacists with annual contest
CAMP HILL, Pa. Rite Aid is asking patients to vote for their favorite pharmacist during the month of October, which is American Pharmacists Month.
Through Oct. 31, Rite Aid patients are encouraged to vote for their favorite pharmacist on RiteAid.com or in any Rite Aid store, an annual contest now in its seventh year. One patient and one pharmacist will each receive $2,500 in Rite Aid gift cards through a random drawing.
“American Pharmacists Month is the perfect time to honor Rite Aid pharmacists for all they do to keep their patients and communities healthy,” said Robert Thompson, Rite Aid EVP pharmacy. “Our pharmacists provide outstanding patient care every day, whether they’re counseling patients on medications, administering immunizations or helping them manage a new or difficult disease. Our Favorite Pharmacist program is a great way for our company and patients to thank them for their hard work and dedication throughout the year.”
KeyVive seeks to improve medication adherence with SMS system
PARK CITY, Utah A healthcare technology company that uses social media and self-management tools to help people with chronic illnesses is launching a mobile health technology designed to improve adherence.
KeyVive said that its Simplatype mHealth technology, a new SMS system, utilizes proprietary technology with existing cell phone carriers to provide an effective way for practitioners and patients to communicate, store conversations and integrate with electronic records, the company said.
“Our company’s mission is to provide the best healthcare opportunities to professionals in the industry, allowing people to succeed in managing their disease, saving time and money,” said David Greenholtz, president and co-founder of KeyVive. “Pilot groups are currently being implemented, and we are very excited to see how individuals will use their phones to improve their outcomes.”
For more information, visit KeyVive.com.